When the reboot of the TV sitcom Roseanne briefly graced our screens earlier this year, before its ignominious exit, it featured something that made me sit up and take notice: the patriarch of the Conner family, Dan Conner, played by John Goodman, was depicted in bed wearing the full face... Show More
One of the more straightforward ways to make money in the pharmaceuticals game is to reformulate someone else's drug once it is off patent. To develop a new drug these days will likely costs a large pharma company more than a billion US dollars and well in excess of ten... Show More
Want a sure-fire way to make money in biotech and medical device stocks? There is none. There are, however, certain things you can do to maximise your chances of success. I have been arguing lately that one of the better ways to do that is by buying stock in companies... Show More
Today we've initiated coverage on Patrys, a Melbourne-based company that may have one of the world's first cell-penetrating antibodies for the treatment of cancer. Show More
I love it when ASX-listed Life Science companies generate pleasant surprises. For the last year or so we at NDF Research have been following Dimerix, a drug developer whose lead candidate, DMX-200, is showing promise in the treatment of kidney disease. DMX-200 is a combination of two existing drugs, irbesartan... Show More
Are you bullish on New Zealand at the moment? If you are, you ought to check out what's going on in the country's emerging Life Sciences scene. This is the country that created Fisher & Paykel Healthcare as well as the A2 Milk Company, and, as Xero has shown us,... Show More
Many experts believe that cancer is gradually transitioning from a death sentence to a manageable disease condition and that 'immuno-oncology', in which the patient's immune system is harnessed to attack the cancer, will be pivotal to the transition. If you read about Melbourne businessman Ron Walker's life being saved by... Show More
Sirtex (ASX: SRX), whose SIR-Spheres product treats liver cancer through localised radiotherapy, had a good FY16, with revenue of A$232m (up 32%) and EBITDA of $70m (up 40%). In constant currency terms revenue rose 17%, in line with dose unit growth, but that was in line with the experience of... Show More
Everyone agrees that mental illness is something we need to do more about. So it's heartening to know that the Australian Life Sciences industry is potentially able to do something about it. A couple of years ago I wrote about a diagnostic tool being developed by a Sydney-based company now... Show More